Tianjin Lisheng Pharmaceutical Co., Ltd. (SHE: 002393), a Chinese pharmaceutical company, has announced plans to sell its 24.65% stake in the Tianjin subsidiary of Japan-based Mitsubishi Tanabe Pharma Corporation. The assessed value of all shareholder equity, calculated using the income method, is RMB 486 million (USD 67.3 million), marking an appreciation of RMB 299.1 million or 160.03%.
The Tianjin subsidiary is a core part of Mitsubishi Tanabe’s operations in China, specializing in the manufacturing and marketing of originator drugs for chronic diseases such as cardiovascular, cerebrovascular, endocrine metabolism, and gastrointestinal disorders. Mitsubishi Tanabe supplies raw materials and some formulation products, which are then produced, repackaged, and sold locally by the Tianjin unit. Key products including Herbesser (diltiazem), Herbesser capsules (diltiazem), Anplag (sarpogrelate), Tanatril (imidapril), and Cerekinon (trimebutine) are manufactured, packaged, and sold by the subsidiary. Additionally, Herbesser injection, Novastan (argatroban), and Tenelia (teneligliptin) are produced by the parent company and sold by the unit after local packaging.- Flcube.com
